

Accepted Manuscript

Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol MDI in COPD

Fernando J. Martinez, MD, FCCP, Leonardo M. Fabbri, MD, FCCP, Gary T. Ferguson, MD, FCCP, Chad Orevillo, MPH, Patrick Darken, PhD, Ubaldo J. Martin, MD, Colin Reisner, MD, FCCP

PII: S0012-3692(17)31254-0

DOI: [10.1016/j.chest.2017.07.007](https://doi.org/10.1016/j.chest.2017.07.007)

Reference: CHEST 1202

To appear in: *CHEST*


Received Date: 17 March 2017

Revised Date: 26 May 2017

Accepted Date: 3 July 2017

Please cite this article as: Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C, Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol MDI in COPD, *CHEST* (2017), doi: 10.1016/j.chest.2017.07.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Abstract word count: 241/250

Total word count: 2683/2500

Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol MDI in COPD

Fernando J. Martinez, MD, FCCP; Leonardo M. Fabbri, MD, FCCP; Gary T. Ferguson, MD, FCCP; Chad Orevillo, MPH; Patrick Darken, PhD; Ubaldo J. Martin, MD; and Colin Reisner, MD, FCCP

AFFILIATIONS: From the Joan and Sanford Weill Department of Internal Medicine (Dr Martinez), Weill Cornell Medicine, New York, NY; Department of Medical and Surgical Sciences (Dr Fabbri), University of Modena and Reggio Emilia, Modena, Italy; Pulmonary Research Institute of Southeast Michigan (Dr Ferguson), Farmington Hills, MI; Biostatistics (Dr Darken), Former employee of Clinical Development (Mr Orevillo), Pearl Therapeutics, Inc., Morristown, NJ; Respiratory Global Medicines (Dr Martin), AstraZeneca, Gaithersburg, MD; CEO (Dr Reisner), Pearl Therapeutics, Inc., Morristown, NJ; and Respiratory Global Medicines, AstraZeneca, Gaithersburg, MD.

CORRESPONDENCE TO: Dr Fernando J. Martinez. Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, 525 East 68th St, New York, NY 10065, USA.

Email: fjm2003@med.cornell.edu.

FUNDING/SUPPORT: PINNACLE-1 and PINNACLE-2 were supported by Pearl Therapeutics Inc., a member of the AstraZeneca Group.

CONFLICTS OF INTEREST: FJM reports personal fees from Adept, Afferent, Amgen, AstraZeneca, Axon, Axon Communication, Boehringer Ingelheim, Clarion, ConCert, Forest, Genentech, GlaxoSmithKline, Ikaria/Bellerophon, Informa, Janssen, Kadmon, Lucid,

Download English Version:

<https://daneshyari.com/en/article/8658148>

Download Persian Version:

<https://daneshyari.com/article/8658148>

[Daneshyari.com](https://daneshyari.com)